Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice

Molecular Medicine

Volumn 18, Issue 4, 2012, Pages 628-635

  Hagemeyer, Nora ^a   Boretius, Susann ^b   Ott, Christoph ^a   Von Streitberg, Axel ^a   Welpinghus, Henrike ^a   Sperling, Swetlana ^a   Frahm, Jens ^b   Simons, Mikael ^a,c   Ghezzi, Pietro ^d   Ehrenreich, Hannelore ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Biomedizinische NMR Forschungs GmbH   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CUPRIZONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BEHAVIOR; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; DRUG MECHANISM; FOOD; HISTOPATHOLOGY; INFLAMMATION; INJECTION; LONGITUDINAL STUDY; MALE; MICROGLIA; MOTOR COORDINATION; MOUSE; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE; VESTIBULAR FUNCTION; WHITE MATTER;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AXONS; CEREBRAL VENTRICLES; CORPUS CALLOSUM; CUPRIZONE; DEMYELINATING DISEASES; ERYTHROPOIETIN; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROPROTECTIVE AGENTS; POSTURAL BALANCE; PSYCHOMOTOR PERFORMANCE;

EID: 84862186613     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00457     Document Type: Article

References (47)

1. Compston A, Coles A. (2002) Multiple sclerosis. Lancet 359:1221-1231.
2. Hauser SL, Oksenberg JR. (2006) The neurobiol-ogy of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 52:61-76.
3. Buck D, Hemmer B. (2011) Treatment of multiple sclerosis: current concepts and future perspectives. J. Neurol. 258:1747-1762.
4. Bartels C, Spate K, Krampe H, Ehrenreich H. (2008) Recombinant human erythropoietin: novel strategies for neuroprotective/neuro-regenerative treatment of multiple sclerosis. Ther. Adv. Neurol. Disord. 1:193-206.
5. Agnello D, et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952:128-134.
6. Brines ML, et al. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97:10526-10531.
7. Chen SJ, et al. (2010) Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162:210-223.
8. Diem R, et al. (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain. 128:375-385.
9. Kang SY, et al. (2009) Expression of erythropoi-etin in the spinal cord of lewis rats with experimental autoimmune encephalomyelitis. J. Clin. Neurol. 5:39-45.
10. Leist M, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 305:239-242.
11. Li W, et al. (2004) Beneficial effect of erythropoi-etin on experimental allergic encephalomyelitis. Ann. Neurol. 56:767-777.
12. Sattler MB, et al. (2004) Neuroprotective effects and intracellular signaling pathways of erythro-poietin in a rat model of multiple sclerosis. Cell Death Differ. 11 (Suppl. 2):S181-S192.
13. Savino C, et al. (2006) Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172:27-37.
14. Thorne M, Moore CS, Robertson GS. (2009) Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbe-poetin alfa on TIMP-1 null and wild-type mice. J. Neuroimmunol. 211:92-100.
15. Yuan R, et al. (2008) Erythropoietin: a potent in-ducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One. 3:e1924.
16. Zhang J, et al. (2005) Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 1034:34-39.
17. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. (2010) Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract. Res. Clin. Anaesthesiol. 24:573-594.
18. Ehrenreich H, et al. (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 130:2577-2588.
19. Ehrenreich H, et al. (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry. 9:42-54.
20. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 6:108-127.
21. Boretius S, Kasper L, Tammer R, Michaelis T, Frahm J. (2009) MRI of cellular layers in mouse brain in vivo. Neuroimage. 47:1252-1260.
22. Vandesompele J, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
23. Merkler D, et al. (2005) Multicontrast MRI of remyelination in the central nervous system. NMR Biomed. 18:395-403.
24. Carlton WW. (1967) Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. Life Sci. 6:11-19.
25. Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M. (2009) Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett. 453:120-125.
26. Matsushima GK, Morell P. (2001) The neurotoxi-cant, cuprizone, as a model to study demyelina-tion and remyelination in the central nervous system. Brain Pathol. 11:107-116.
27. Song SK, et al. (2005) Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage. 26:132-140.
28. Tsiperson V, Li X, Schwartz GJ, Raine CS, Shafit-Zagardo B. (2010) GAS6 enhances repair following cuprizone-induced demyelination. PLoS One. 5:e15748.
29. Sargin D, Hassouna I, Sperling S, Siren AL, Ehrenreich H. (2009) Uncoupling of neurodegen-eration and gliosis in a murine model of juvenile cortical lesion. Glia. 57:693-702.
30. Jung KH, et al. (2011) Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin. Epilepsia. 52:541-550.
31. Yatsiv I, et al. (2005) Erythropoietin is neuropro-tective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 19:1701-1703.
32. Villa P, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apo-ptosis. J. Exp. Med. 198:971-975.
33. Iwai M, et al. (2010) Enhanced oligodendrogene-sis and recovery of neurological function by ery-thropoietin after neonatal hypoxic/ischemic brain injury. Stroke. 41:1032-1037.
34. Wergeland S, et al. (2011) Dietary vitamin D3 supplements reduce demyelination in the cupri-zone model. PLoS One. 6:e26262.
35. Ji Y, Kutner A, Verstuyf A, Verlinden L, Studzin-ski G P. (2002) Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle. 1:410-415.
36. Dusso AS, Puche RC. (1985) The effect of 1 alpha, 25-dihydroxycholecalciferol on iron metabolism. Blut. 51:103-108.
37. Skliar MI, et al. (1980) Effect of 1,25-dihydroxyc-holecalciferol and 1,25-dihydroxycholecalciferol glycoside on 2,3-diphosphoglycerate levels of the rat erythrocyte. Pflugers Arch. 389:81-83.
38. Liebetanz D, Merkler D. (2006) Effects of com-missural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp. Neurol. 202:217-224.
39. Kipp M, Clarner T, Dang J, Copray S, Beyer C. (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol. 118:723-736.
40. Liu L, et al. (2010) CXCR2-positive neutrophils are essential for cuprizone-induced demyelina-tion: relevance to multiple sclerosis. Nat. Neurosci. 13:319-326.
41. Chen G, et al. (2007) Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuropro-tective mechanism of recombinant human ery-thropoietin (rhEPO). Neurosci. Lett. 425:177-182.
42. Mausberg AK, et al. (2011) Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages. PLoS One. 6:e26280.
43. Sun Y, Calvert JW, Zhang JH. (2005) Neonatal hy-poxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke. 36:1672-1678.
44. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. (2001) Interleukin-1beta promotes repair of the CNS. J. Neurosci. 21:7046-7052.
45. Gudi V, et al. (2011) Spatial and temporal profiles of growth factor expression during CNS de-myelination reveal the dynamics of repair priming. PLoS One. 6:e22623.
46. Voss E V, et al. (2012) Characterisation of mi-croglia during de- and remyelination: can they create a repair promoting environment? Neuro-biol. Dis. 45:519-528.
47. Schmid CD, et al. (2009) Differential gene expression in LPS/IFNgamma activated microglia and macrophages: in vitro versus in vivo. J. Neu-rochem. 109 (Suppl. 1):117-125.